Novel antibodies directed against the human erythropoietin receptor: Creating a basis for clinical implementation

Perry Maxwell, Florinda Melendez-Rodríguez, Kyle B. Matchett, Julian Aragones, Nathalie Ben-Califa, Heidelinde Jaekel, Ludger Hengst, Herbert Lindner, Andre Bernardini, Ulf Brockmeier, Joachim Fandrey, Fritz Grunert, Howard S. Oster, Moshe Mittelman, Mohamed El-Tanani, Markus Thiersch, Edith M. Schneider Gasser, Max Gassmann, David Dangoor, Robert J. CuthbertAlexandra Irvine, Anne Jordan, Terence Lappin, John Thompson, Drorit Neumann

Research output: Contribution to journalArticlepeer-review


Recombinant human erythropoietin (rHuEPO) is an effective treatment for anaemia but concerns that it causes disease progression in cancer patients by activation of EPO receptors (EPOR) in tumour tissue have been controversial and have restricted its clinical use. Initial clinical studies were flawed because they used polyclonal antibodies, later shown to lack specificity for EPOR. Moreover, multiple isoforms of EPOR caused by differential splicing have been reported in cancer cell lines at the mRNA level but investigations of these variants and their potential impact on tumour progression, have been hampered by lack of suitable antibodies. The EpoCan consortium seeks to promote improved pathological testing of EPOR, leading to safer clinical use of rHuEPO, by producing well characterized EPOR antibodies. Using novel genetic and traditional peptide immunization protocols, we have produced mouse and rat monoclonal antibodies, and show that several of these specifically recognize EPOR by Western blot, immunoprecipitation, immunofluorescence, flow cytometry and immunohistochemistry in cell lines and clinical material. Widespread availability of these antibodies should enable the research community to gain a better understanding of the role of EPOR in cancer, and eventually to distinguish patients who can be treated safely by rHuEPO from those at increased risk from treatment.

Original languageEnglish
Pages (from-to)429-442
Number of pages14
JournalBritish Journal of Haematology
Issue number3
StatePublished - 1 Feb 2015


  • Antibody
  • Cancer anaemia
  • Erythropoietin receptor
  • Recombinant erythropoietin
  • Risk assessment

All Science Journal Classification (ASJC) codes

  • Hematology


Dive into the research topics of 'Novel antibodies directed against the human erythropoietin receptor: Creating a basis for clinical implementation'. Together they form a unique fingerprint.

Cite this